Vasopressin Injection
NDC Package 68083-520-10
Package Information
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. This formulation utilizes a injection delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-520 and is authorized under FDA application ANDA216963.
Identification & Billing
- RxCUI: 2103182 - vasopressin 20 UNT in 1 mL Injection
- RxCUI: 2103182 - 1 ML vasopressin (USP) 20 UNT/ML Injection
- RxCUI: 2103182 - vasopressin 20 UNT per 1 ML Injection
- RxCUI: 2399907 - vasopressin (USP) 40 UNT in 100 ML Injection
- RxCUI: 2399907 - 100 ML vasopressin (USP) 0.4 UNT/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-520 - Vasopressin
- 68083-520-10 - 10 VIAL in 1 CARTON / 1 mL in 1 VIAL
- 68083-520 - Vasopressin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68083-520). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-520-10 identifies a specific commercial package of 10 vial in 1 carton / 1 ml in 1 vial of Vasopressin, a human prescription drug labeled by Gland Pharma Limited. This injection is formulated for intravenous use and contains vasopressin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on February 09, 2024. The current certification is valid through December 31, 2026.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083052010. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.